NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) resulting from allegations that MoonLake may have issued materially misleading business information to the investing public. SO WHAT: If you purchased MoonLake securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency f ...

Accessibility StatementSkip Navigation NEW YORK, Oct. 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) resulting from allegations that MoonLake may have issued materially misleading business information to the investing public. So What: If you purchased MoonLake securities you may be entitled to compensation without payment of any out of pocket fees or c ...

Core Points - Bragar Eagel & Squire, P.C. is investigating potential claims against MoonLake Immunotherapeutics for possible violations of federal securities laws and unlawful business practices [1][2][4] - MoonLake's stock experienced a significant decline of 89.9% on September 29, 2025, following the announcement of disappointing results from its VELA-2 trial, which failed to achieve statistical significance [1][6] Investigation Details - The law firm is reaching out to investors who purchased or acquired MoonLake shares and suffered losses, encouraging them to discuss their legal rights and options [1][3] - The investigation is focused on whether the company misled investors regarding its trial results and overall business practices [1][2] Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation [4] - The firm operates in multiple states, including New York, South Carolina, and California, and has a track record in commercial and securities litigation [4]

Core Viewpoint - DJS Law Group is investigating claims against MoonLake Immunotherapeutics for potential violations of securities laws, particularly related to misleading statements about its VELA-2 clinical trial [1][2]. Investigation Details - The investigation centers on whether MoonLake made misleading statements or failed to disclose critical information to investors. The company's communications regarding the VELA-2 clinical trial were deemed overly optimistic until September 29, 2025, when it announced that unexpected events in the placebo group prevented the study from achieving statistical significance in its primary endpoint, resulting in a 90% decline in share value [2]. Company Background - MoonLake Immunotherapeutics is a publicly traded company on NASDAQ under the ticker MLTX. The company is currently facing scrutiny due to the recent developments in its clinical trial results [1]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing sophisticated hedge funds and alternative asset managers. The firm emphasizes the importance of protecting investor rights and maximizing returns through legal advocacy [4].

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics. Why Is MoonLake being Investigated?MoonLake is a clinical stage biotechnology company focusing on therapies to address inflammato ...

LOS ANGELES--(BUSINESS WIRE)--MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX. ...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) resulting from allegations that MoonLake may have issued materially misleading business information to the investing public. So What: If you purchased MoonLake securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar. ...

LOS ANGELES--(BUSINESS WIRE)---- $MLTX--MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm. ...

SAN FRANCISCO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) saw the price of their shares crater $55.75, or about 90%, after the company announced disastrous VELA-2 trial results for sonelokimab, its highly anticipated treatment for patients with skin disease (hidradenitis suppurative or “HS”). The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether MoonLake may have misled inv ...

NEW YORK--(BUSINESS WIRE)---- $MLTX #BFALaw--MoonLake Immunotherapeutics investors that lost money are notified to contact BFA Law about its ongoing securities fraud class action investigation. ...